While traditional diagnostics such as prostate-specific antigen testing and biopsy have long been the cornerstone of prostate cancer detection and risk stratification, advances in molecular profiling have introduced gene expression classifiers that offer a deeper understanding of tumor biology. This evidence concerns the gene KLK3 and Familial prostate cancer.